FNCHQ (Finch Therapeutics Group) Beginning Cash Position: $23.11 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group Beginning Cash Position?

Finch Therapeutics Group FNCHQ 12 Beginning Cash Position is $23.11 Mil as of Jun. 2024. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

Finch Therapeutics Group's Beginning Cash Position for the quarter that ended in Jun. 2024 was $23.11 Mil.

Finch Therapeutics Group's quarterly Beginning Cash Position declined from Dec. 2023 ($31.13 Mil) to Mar. 2024 ($27.47 Mil) and declined from Mar. 2024 ($27.47 Mil) to Jun. 2024 ($23.11 Mil).

Finch Therapeutics Group's annual Beginning Cash Position increased from Dec. 2021 ($99.91 Mil) to Dec. 2022 ($135.97 Mil) but then declined from Dec. 2022 ($135.97 Mil) to Dec. 2023 ($73.81 Mil).

Finch Therapeutics Group Beginning Cash Position Related Terms

Finch Therapeutics Group Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group Beginning Cash Position Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
7.39 42.40 99.91 135.97 73.81

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.25 36.37 31.13 27.47 23.11
FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $23.11 Mil mean?
Finch Therapeutics Group (FNCHQ) has a Beginning Cash Position of $23.11 Mil as of Jun. 2024. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Beginning Cash Position too high?
Finch Therapeutics Group's current Beginning Cash Position is $23.11 Mil. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Beginning Cash Position compare to CRIS and LSB?
Finch Therapeutics Group's Beginning Cash Position of $23.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current Beginning Cash Position is $23.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Beginning Cash Position of $23.11 Mil. The current Beginning Cash Position is $23.11 Mil. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Beginning Cash Position is $23.11 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price